Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: The Single Most Important Factor In Determining The Future Of SBRT Is Immune Response

C. Grassberger, K. Huber, N. Jacob, M. Green, P. Mahler, J. Prisciandaro, M. Dominello, M. Joiner, J. Burmeister
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Radiation Oncology is a highly multidisciplinary medical specialty, drawing significantly from three scientific disciplines — medicine, physics, and biology. As a result, discussion of controversies or changes in practice within radiation oncology involves input from all three disciplines. For this reason, significant effort has been expended recently to foster collaborative multidisciplinary research in radiation oncology, with substantial demonstrated benefit. In light of these results, we endeavor here to adopt this “team‐science” approach to the traditional debates featured in this journal. This article is part of a series of special debates entitled “Three Discipline Collaborative Radiation Therapy (3DCRT)” in which each debate team will include a radiation oncologist, medical physicist, and radiobiologist. We hope that this format will not only be engaging for the readership but will also foster further collaboration in the science and clinical practice of radiation oncology.
This paper references
10.1016/j.prro.2015.01.004
Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons.
S. Gandhi (2015)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.3109/02841869509127197
Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.
H. Blomgren (1995)
10.1016/S1470-2045(14)70189-5
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
E. Kwon (2014)
10.1016/j.ijrobp.2008.11.042
Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
A. Fakiris (2009)
10.1016/S1042-3680(18)30192-X
Extracranial stereotactic radiosurgery: applications for the spine and beyond.
I. Takács (1999)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1586/14737140.2014.940326
The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors
A. Jain (2014)
10.1016/S0093-7754(03)00350-6
Immunotherapy for prostate cancer.
L. Fong (2007)
10.1016/S0140-6736(15)01281-7
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
10.3322/caac.21551
Cancer statistics, 2019
R. Siegel (2019)
10.1002/cam4.2100
Using adaptive magnetic resonance image‐guided radiation therapy for treatment of inoperable pancreatic cancer
S. Rudra (2019)
10.1007/s10147-014-0717-z
Radiobiological basis of SBRT and SRS
C. Song (2014)
Abstract P 2 – 09 ‐ 07 : Preoperative pem - brolizumab ( Pembro ) with radiation therapy ( RT ) in patients with operable triple ‐ negative breast cancer ( TNBC )
HL McArthur (2019)
10.3109/02841869409121782
Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects.
Ingmar Lax (1994)
10.3390/cancers10120497
Developments in Stereotactic Body Radiotherapy
A. Haridass (2018)
10.1186/s13014-019-1237-9
Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous
C. Nieder (2019)
10.1227/00006123-199502000-00010
Preliminary clinical experience with linear accelerator-based spinal stereotactic radiosurgery.
A. Hamilton (1995)
10.1200/JCO.2008.16.4855
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
G. Strauss (2008)
10.1200/JCO.2015.61.4925
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
D. Wahl (2016)
10.1016/j.ijrobp.2013.07.022
The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?
J. Brown (2014)
10.1118/1.3438081
Stereotactic body radiation therapy: the report of AAPM Task Group 101.
S. Benedict (2010)
10.1001/jamaoncol.2015.2756
Role of Local Radiation Therapy in Cancer Immunotherapy.
S. Demaria (2015)
10.1016/j.ijrobp.2015.11.026
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
A. Wild (2016)
10.1038/nrd.2018.210
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
J. Tang (2018)
10.1002/(SICI)1097-0142(19980315)82:6<1062::AID-CNCR8>3.0.CO;2-G
Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients
M. Uematsu (1998)
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
10.1038/nrd4338
Learning from exceptional drug responders
A. Mullard (2014)
10.1097/COC.0000000000000706
ACR–ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy
S. Chao (2020)
10.1667/RR2773.1
Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS)
H. Park (2012)
10.1111/j.1365-2141.2009.07710.x
Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party
K. Wheatley (2009)
10.1016/j.ejmp.2017.12.020
The impact of technology on the changing practice of lung SBRT
M. Aznar (2018)
10.21037/cco.2017.07.01
Re-irradiation with stereotactic body radiation therapy (SBRT).
M. Høyer (2017)
10.1016/J.IJROBP.2018.06.105
Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial
D. Palma (2018)
10.1016/j.ijrobp.2018.01.045
…of Radiation Oncology, Biology, and Physics.
J. Burmeister (2018)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
10.1016/j.ijrobp.2018.09.010
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.
Luke R. G. Pike (2019)
10.1016/j.ijrobp.2018.08.022
Radiation Therapy Outcomes Models in the Era of Radiomics and Radiogenomics: Uncertainties and Validation.
I. El Naqa (2018)
10.1016/S0140-6736(18)32486-3
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
C. Parker (2018)
10.1016/j.ijrobp.2018.05.040
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Robert M. Meier (2018)
10.1016/j.ijrobp.2019.03.051
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
W. Jackson (2019)
10.1200/JCO.2008.19.6329
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
Kyle E. Rusthoven (2009)
10.1002/acm2.12796
Expanding the reach of medical physics: Immunotherapy should be included as part of the curriculum for medical physics education and training
N. Lamichhane (2019)
10.1159/000106045
The promise of stereotactic body radiation therapy in a new era of oncology.
B. Kavanagh (2007)
10.1016/j.adro.2018.08.021
Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation
E. C. Ko (2018)
10.1056/NEJMoa1709684
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Wolchok (2017)
10.1158/1078-0432.CCR-17-3375
The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients
M. Vozenin (2018)
10.1002/hed.24633
Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review
S. Baliga (2017)
10.1200/jco.2009.27.15_suppl.8071
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
P. Zatloukal (2009)
10.1667/RR15023.1
Improving Research in Radiation Oncology through Interdisciplinary Collaboration
J. Burmeister (2018)
10.1097/JTO.0b013e318074de34
Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study
H. Onishi (2007)
10.1038/ncomms15618
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box (2017)
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
GY Ku (2010)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.1186/1748-717X-9-210
Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review
A. Amini (2014)
10.3389/fonc.2018.00171
Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors
R. Baumann (2018)
Anniversary Paper: the role of medical physicists in developing stereotactic radiosurgery.
S. Benedict (2008)
10.1093/ANNONC/MDY270.265
Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC).
H. L. McArthur (2018)
10.1126/scitranslmed.aad7118
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
W. Zou (2016)
10.3389/fimmu.2017.01476
Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer
E. Muraro (2017)
10.1001/jamaoncol.2019.1478
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
W. S. Theelen (2019)
10.1016/j.prro.2011.10.004
Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control.
N. Mehta (2012)
10.1038/s41591-018-0232-2
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
S. Formenti (2018)
10.1016/J.IJROBP.2018.08.050
Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial
Daniel R. Gomez (2018)
10.1038/nrc.2018.6
Using immunotherapy to boost the abscopal effect
W. Ngwa (2018)
10.1158/1078-0432.CCR-18-0380
Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?
S. Lheureux (2018)
10.1155/2017/4279724
Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment
C. Speers (2017)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar